JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR)

JMP Securities reiterated their market outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note released on Friday, Benzinga reports. They currently have a $70.00 target price on the stock.

JSPR has been the subject of several other research reports. Stifel Nicolaus initiated coverage on shares of Jasper Therapeutics in a research report on Thursday, June 27th. They set a buy rating and a $86.00 price target for the company. Cantor Fitzgerald restated an overweight rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Evercore ISI reiterated an outperform rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Monday, August 26th. BTIG Research started coverage on Jasper Therapeutics in a research note on Monday, July 8th. They issued a buy rating and a $90.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on shares of Jasper Therapeutics from $70.00 to $68.00 and set an outperform rating on the stock in a research note on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of Buy and an average target price of $73.00.

Jasper Therapeutics Trading Down 0.1 %

Shares of JSPR stock opened at $18.81 on Friday. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01. The business’s 50 day moving average is $19.61 and its two-hundred day moving average is $22.41. The company has a market capitalization of $283.35 million, a P/E ratio of -3.34 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. On average, research analysts predict that Jasper Therapeutics will post -4.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Opaleye Management Inc. purchased a new stake in shares of Jasper Therapeutics during the 4th quarter valued at approximately $3,144,000. Kingdon Capital Management L.L.C. grew its holdings in shares of Jasper Therapeutics by 16.4% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after purchasing an additional 500,000 shares during the period. StemPoint Capital LP acquired a new stake in shares of Jasper Therapeutics during the 1st quarter worth about $3,794,000. Ikarian Capital LLC purchased a new stake in Jasper Therapeutics in the 1st quarter valued at about $3,088,000. Finally, Russell Investments Group Ltd. acquired a new position in Jasper Therapeutics in the first quarter valued at about $2,343,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.